GLP-1 and metabolic
Retatrutide Phase 3: The TRIUMPH Trials and What Has Reported
AM
· 9 min read
A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
On this page · 9 sections
Retatrutide's phase 3 programme is large and only partly reported. ClinicalTrials.gov lists nine numbered TRIUMPH trials in obesity, plus a cardiovascular and kidney outcomes trial and three TRANSCEND trials in type 2 diabetes. By October 2026, results had been published from TRIUMPH-1, TRIUMPH-2, their nested sleep apnoea trials and TRANSCEND-T2D-1. In TRIUMPH-1, mean weight change at 80 weeks reached −25.0% against −3.9% on placebo. Retatrutide remains investigational and approved nowhere.

What is the TRIUMPH programme?
Retatrutide (LY3437943) is Eli Lilly's single-peptide agonist of the GIP, GLP-1 and glucagon receptors. The retatrutide overview covers the pharmacology and the phase 2 trials. TRIUMPH is the name of its phase 3 obesity programme, and TRANSCEND is the name used for its type 2 diabetes and kidney trials.
The core of TRIUMPH uses an unusual design. A rationale paper by Giblin and colleagues describes four registrational trials with more than 5,800 participants. Two of them, TRIUMPH-1 and TRIUMPH-2, are "basket" trials: one weight-management trial with smaller trials in knee osteoarthritis and obstructive sleep apnoea nested inside it. The participants with those conditions count towards the weight endpoint and also have their own primary endpoint. The type I error rate is split between the weight trial and each basket, so each nested result is tested in its own right rather than mined out of the main trial afterwards.
Which phase 3 trials are registered?
This table is drawn from ClinicalTrials.gov registry entries as of October 2026. Enrolment figures marked "estimated" are the sponsor's targets.
| Trial | Registry | Population | Primary endpoint(s) | Status |
|---|---|---|---|---|
| TRIUMPH-1 | NCT05929066 | Obesity or overweight without diabetes, with knee osteoarthritis and sleep apnoea baskets | Weight at week 80; WOMAC pain; apnoea–hypopnoea index | Completed, published |
| TRIUMPH-2 | NCT05929079 | Obesity or overweight with type 2 diabetes, with a sleep apnoea basket | Weight at week 80; apnoea–hypopnoea index | Completed, published |
| TRIUMPH-3 | NCT05882045 | Obesity with established cardiovascular disease, 1,946 enrolled | Weight at week 80 | Completed; no paper found on PubMed |
| TRIUMPH-4 | NCT05931367 | Obesity or overweight with knee osteoarthritis, 445 enrolled | WOMAC pain and weight at week 68 | Completed; no paper found on PubMed |
| TRIUMPH-5 | NCT06662383 | Obesity; head-to-head against tirzepatide, about 800 estimated | Weight at week 80 | Active, not recruiting |
| TRIUMPH-6 | NCT06859268 | Maintenance of weight reduction, about 643 estimated | Weight at week 116 | Active, not recruiting |
| TRIUMPH-7 | NCT07035093 | Obesity or overweight with chronic low back pain | Pain score and weight, up to 72 weeks | Active, not recruiting |
| TRIUMPH-8 | NCT07232719 | Obesity or overweight, about 250 estimated | Weight at week 56 | Active, not recruiting |
| TRIUMPH-9 | NCT07357415 | Obesity or overweight without diabetes, about 600 estimated | Weight at week 104 | Active, not recruiting |
| TRIUMPH-Outcomes | NCT06383390 | Obesity with cardiovascular or chronic kidney disease, about 10,000 estimated | Time to cardiovascular and kidney composite events | Active, not recruiting; primary completion listed for 2029 |
| TRANSCEND-T2D-1 | NCT06354660 | Type 2 diabetes on diet and exercise alone | HbA1c at week 40 | Completed, published |
| TRANSCEND-T2D-2 | NCT06260722 | Type 2 diabetes on metformin; head-to-head against semaglutide | HbA1c at week 80 | Active, not recruiting |
| TRANSCEND-T2D-3 | NCT06297603 | Type 2 diabetes with moderate or severe kidney impairment | HbA1c at week 52 | Active, not recruiting |
Registry entries record what a sponsor planned and reports. They change, and a "completed" status says nothing about what a trial found. Retatrutide is also one of several agents in SYNERGY-Outcomes (NCT07165028), a platform outcomes trial testing several agents in metabolic dysfunction-associated steatotic liver disease.
What did TRIUMPH-1 report?
TRIUMPH-1 randomised 2,339 adults with obesity and without diabetes to one of three retatrutide dose levels or placebo for 80 weeks. Weight was analysed with a treatment-regimen estimand, which counts everyone randomised whether or not they stayed on treatment. Mean weight change was −17.6%, −23.7% and −25.0% across the three groups in ascending order, against −3.9% on placebo.
In the 574 participants with knee osteoarthritis, WOMAC pain scores fell by 3.2 to 3.6 points against 1.9 on placebo using the trial's hybrid estimand, and by 3.4 to 4.1 against 2.5 using intention to treat. In the 243 participants with sleep apnoea, the apnoea–hypopnoea index fell by 22.9 to 34.3 events per hour against 9.9 on placebo. The most common adverse events were gastrointestinal. The abstract does not give their rates.
What did TRIUMPH-2 report?
TRIUMPH-2 enrolled 1,152 adults with obesity and type 2 diabetes at 92 centres in eight countries. Mean baseline BMI was 38.2 and mean HbA1c 7.71%, and 84% completed study treatment. At 80 weeks, mean weight change was −11.9%, −16.8% and −18.8% across retatrutide groups against −5.1% on placebo. The smaller figures than in TRIUMPH-1 fit a pattern seen across this drug class: weight reduction is generally smaller in people with type 2 diabetes.
TRIUMPH-2 is also where the most detailed phase 3 safety data have appeared, including more hypotension, dysesthesia (abnormal skin sensation) and discontinuations than on placebo. Those findings are set out in the retatrutide side-effects article.
What did the sleep apnoea trials report?
The sleep apnoea baskets of TRIUMPH-1 and TRIUMPH-2 were reported together by Grunstein and colleagues. TRIUMPH-1-OSA randomised 243 participants without diabetes and TRIUMPH-2-OSA 448 with diabetes. Baseline apnoea–hypopnoea index averaged 58.6 and 55.9 events per hour, which is severe. At 80 weeks, the placebo-adjusted difference at the two higher dose levels was −24.4 and −21.9 events per hour in TRIUMPH-1-OSA, and −14.4 and −15.1 in TRIUMPH-2-OSA. How such endpoints are measured is covered in the tirzepatide sleep apnoea article.
What did TRANSCEND-T2D-1 report?
TRANSCEND-T2D-1 is the first published phase 3 trial with a glycaemic primary endpoint. It randomised 537 adults with type 2 diabetes managed with diet and exercise alone, at 48 sites in the USA, Mexico and India, for 40 weeks. HbA1c fell by 1.69 to 1.94 percentage points across retatrutide groups against 0.81 on placebo, and weight fell by 11.5% to 15.3% against 2.6%. Discontinuation for adverse events was 2% to 5% with retatrutide and 0% with placebo, and no severe hypoglycaemia was reported.
What does phase 3 still not tell us?
Whether it beats tirzepatide. TRIUMPH-5 is the first head-to-head trial in obesity, and TRANSCEND-T2D-2 compares retatrutide with semaglutide in diabetes. Until they report, comparing retatrutide's numbers with other drugs' trials is a cross-trial comparison, with all the problems that brings. The tirzepatide vs retatrutide article covers why.
What happens to cardiovascular and kidney events. Weight and HbA1c are intermediate measures. TRIUMPH-Outcomes, with about 10,000 participants, is the trial designed to count heart attacks, strokes, cardiovascular deaths and kidney failure.
What happens after stopping or over years. TRIUMPH-6 tests maintenance, and TRIUMPH-1's extension subset follows weight to week 104. No trial has yet reported what happens when treatment ends.
The results of trials already completed. TRIUMPH-3, in people with cardiovascular disease, and TRIUMPH-4, in knee osteoarthritis, are listed as completed, but no peer-reviewed paper for either appeared on PubMed by October 2026. Results that exist only as company announcements have not been through peer review and are not summarised here.
Is retatrutide approved?
No. Retatrutide is not approved by Health Canada, the US Food and Drug Administration, the European Medicines Agency or any other regulator, for any use. Published phase 3 results are evidence a regulator will weigh. They are not an authorisation. In Canada, an authorised drug carries a Drug Identification Number searchable in the Drug Product Database. Why trial results do not transfer to product sold under the same name outside trials is explained in gray-market retatrutide and the evidence.
Supplied here for laboratory use: Retatrutide. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.
The trial results on this page describe Lilly's investigational product in screened trial participants. They are not evidence about any laboratory reagent. Nothing here is medical, dosing, or therapeutic guidance.
Frequently asked questions
How many retatrutide phase 3 trials are there? ClinicalTrials.gov lists nine numbered TRIUMPH trials, a TRIUMPH-Outcomes cardiovascular and kidney trial, and three TRANSCEND trials in type 2 diabetes, plus a liver outcomes platform trial that includes retatrutide. Not all of these are registrational, and only TRIUMPH-1, TRIUMPH-2, their sleep apnoea substudies and TRANSCEND-T2D-1 had published results by October 2026.
What was the weight loss in retatrutide phase 3? In TRIUMPH-1, adults with obesity and without diabetes had mean weight change of −17.6% to −25.0% across the three dose levels at 80 weeks, against −3.9% on placebo. In TRIUMPH-2, in people with type 2 diabetes, it was −11.9% to −18.8% against −5.1%. Both used an estimand that counts everyone randomised.
Is there a phase 3 trial comparing retatrutide with tirzepatide? Yes. TRIUMPH-5 (NCT06662383) randomises adults with obesity to retatrutide or tirzepatide, with weight change at 80 weeks as the primary endpoint. ClinicalTrials.gov lists it as active and no longer recruiting, with primary completion expected in late 2026. No results have been published.
When will retatrutide be approved? No date can be given honestly. Approval depends on regulators reviewing the full dossier, including manufacturing and long-term safety, and on the completed trials that have not yet published. Projected timelines in news coverage are forecasts. As of October 2026, no regulator anywhere has approved retatrutide for any use.
What is a basket trial? A basket trial enrols one broad population and nests smaller trials for specific conditions inside it. In TRIUMPH-1 and TRIUMPH-2, participants with knee osteoarthritis or sleep apnoea counted towards the weight endpoint and also had their own prespecified primary endpoint. The statistical error rate was split in advance so each basket stands as its own test.
Selected Research References
- Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism. 2026;28(1):83-93. pubmed.ncbi.nlm.nih.gov/41090431
- Jastreboff AM, Kaplan LM, Davies MJ, et al.; TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. 2026. pubmed.ncbi.nlm.nih.gov/42814954
- Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. 2026;408(10563):1455-1472. pubmed.ncbi.nlm.nih.gov/42810372
- Grunstein RR, Somers VK, Azarbarzin A, et al.; TRIUMPH-1-OSA and TRIUMPH-2-OSA Investigators. Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea. New England Journal of Medicine. 2026. pubmed.ncbi.nlm.nih.gov/42904878
- Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet. 2026;407(10546):2402-2413. pubmed.ncbi.nlm.nih.gov/42250575
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. pubmed.ncbi.nlm.nih.gov/37366315
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.
